• 1
    Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 1971; 136:6124.
  • 2
    Mold C, Nakayama S, Holzer TJ, Gewurz H, Du Clos TW. C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med 1981; 154:17038.
  • 3
    Yother J, Volanakis JE, Briles DE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol 1982; 128:23746.
  • 4
    Szalai AJ, Briles DE, Volanakis JE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 1995; 155:255763.
  • 5
    Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34:141212.
  • 6
    Carlucci F, Cook HT, Garg A, Pepys MB, Botto M. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum 2010; 62:2459.
  • 7
    de Beer FC, Pepys MB. Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods 1982; 50:1731.
  • 8
    Molden DP, Nakamura RM, Tan EM. Standardization of the immunofluorescence test for autoantibody to nuclear antigens (ANA): use of reference sera of defined antibody specificity. Am J Clin Pathol 1984; 82:5766.
  • 9
    Noursadeghi M, Bickerstaff MCM, Gallimore JR, Herbert J, Cohen J, Pepys MB. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci USA 2000; 97:145849.
  • 10
    Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP) -deficient mice. J Biol Chem 2011; 286:62729.
  • 11
    Pepys MB, Baltz M, Gomer K, Davies AJS, Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 1979; 278:25961.
  • 12
    Pepys MB, Lanham JG, de BF. C-reactive protein in systemic lupus erythematosus. In: Hughes GRV, ed. Clinics in the Rheumatic Diseases, 1st edn. Eastbourne: W.B. Saunders Co Ltd, 1982: 91103.
  • 13
    Pepys MB, Butler PJG. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 1987; 148:30813.
  • 14
    Butler PJG, Tennent GA, Pepys MB. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med 1990; 172:138.
  • 15
    Hirschfield GM, Herbert J, Kahan MC, Pepys MB. Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. J Immunol 2003; 171:604651.
  • 16
    Sørensen UBS, Agger R, Bennedsen J, Henrichsen J. Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody. Infect Immun 1984; 43:8768.
  • 17
    Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid 1997; 4:27495.
  • 18
    Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982; 156:117785.
  • 19
    McCullers JA, Tuomanen EI. Molecular pathogenesis of pneumococcal pneumonia. Front Biosci 2001; 6:D87789.
  • 20
    Agrawal A, Suresh MV, Singh SK, Ferguson DA Jr. The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets 2008; 8:2317.
  • 21
    Volanakis JE, Wirtz KWA. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 1979; 281:1557.
  • 22
    de Beer FC, Soutar AK, Baltz ML, Trayner I, Feinstein A, Pepys MB. Low density and very low density lipoproteins are selectively bound by aggregated C-reactive protein. J Exp Med 1982; 156:23042.
  • 23
    Hart SP, Alexander KM, MacCall SM, Dransfield I. C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages. J Inflamm (Lond) 2005; 2:5.
  • 24
    Guo WX, Burger AM, Fischer RT, Sieckmann DG, Longo DL, Kenny JJ. Sequence changes at the V-D junction of the VH1 heavy chain of anti-phosphocholine antibodies alter binding to and protection against Streptococcus pneumoniae. Int Immunol 1997; 9:66577.
  • 25
    Mukerji R, Mirza S, Roche AM et al. Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol 2012; 189:532735.
  • 26
    Harnett W, Harnett MM. Phosphorylcholine: friend or foe of the immune system? Immunol Today 1999; 20:1259.
  • 27
    Roy S, Hill AV, Knox K, Griffiths D, Crook D. Research pointers: association of common genetic variant with susceptibility to invasive pneumococcal disease. BMJ 2002; 324:1369.
  • 28
    Eklund C, Huttunen R, Syrjänen J, Laine J, Vuento R, Hurme M. Polymorphism of the C-reactive protein gene is associated with mortality in bacteraemia. Scand J Infect Dis 2006; 38:106973.
  • 29
    Mukamal KJ, Pai JK, O'Meara ES et al. CRP gene variation and risk of community-acquired pneumonia. Respirology 2010; 15:1604.